Effects of chronic administration of clenbuterol on contractile properties and calcium homeostasis in rat extensor digitorum longus muscle
Pascal Sirvent, Aymeric Douillard, Olivier Galbes, Christelle Ramonatxo, Guillaume Py, Robin Candau, Alain Lacampagne

To cite this version:
Pascal Sirvent, Aymeric Douillard, Olivier Galbes, Christelle Ramonatxo, Guillaume Py, et al.. Effects of chronic administration of clenbuterol on contractile properties and calcium homeostasis in rat extensor digitorum longus muscle. PLoS ONE, Public Library of Science, 2014, 9 (6), 10.1371/journal.pone.0100281. hal-01837577

HAL Id: hal-01837577
https://hal.archives-ouvertes.fr/hal-01837577
Submitted on 28 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Effects of Chronic Administration of Clenbuterol on Contractile Properties and Calcium Homeostasis in Rat Extensor Digitorum Longus Muscle

Pascal Sirvent1,2,3,4, Aymeric Douillard4, Olivier Galbes2,3,4, Christelle Ramonatxo2,3,4, Guillaume Py4, Robin Candau4, Alain Lacampagne2,3

1 Clermont Université, Université Blaise Pascal, EA 3533, Laboratoire des Adaptations Météaboliques à l’Exercice en Conditions Physiologiques et Pathologiques (AME2P), BP 80026, Aubière, France, 2 U1046, INSERM, Université Montpellier 1, Université Montpellier 2, 34295 Montpellier, France, 3 CHRU Montpellier, 34295 Montpellier, France, 4 National Institute for Agronomic Research (INRA), UMR 866 Muscular Dynamic and Metabolism, University of Montpellier, Montpellier, France

Abstract

Clenbuterol, a β2-agonist, induces skeletal muscle hypertrophy and a shift from slow-oxidative to fast-glycolytic muscle fiber type profile. However, the cellular mechanisms of the effects of chronic clenbuterol administration on skeletal muscle are not completely understood. As the intracellular Ca2+ concentration must be finely regulated in many cellular processes, the aim of this study was to investigate the effects of chronic clenbuterol treatment on force, fatigue, intracellular calcium (Ca2+) homeostasis and Ca2+-dependent proteolysis in fast-twitch skeletal muscles (the extensor digitorum longus, EDL, muscle), as they are more sensitive to clenbuterol-induced hypertrophy. Male Wistar rats were chronically treated with 4 mg.kg-1 clenbuterol or saline vehicle (controls) for 21 days. Confocal microscopy was used to evaluate sarcoplasmic reticulum Ca2+ load, Ca2+-transient amplitude and Ca2+ spark properties. EDL muscles from clenbuterol-treated animals displayed hypertrophy, a shift from slow to fast fiber type profile and increased absolute force, while the relative force remained unchanged and resistance to fatigue decreased compared to control muscles from rats treated with saline vehicle. Compared to control animals, clenbuterol treatment decreased Ca2+-transient amplitude, Ca2+ spark amplitude and frequency and the sarcoplasmic reticulum Ca2+ load was markedly reduced. Conversely, calpain activity was increased by clenbuterol chronic treatment. These results indicate that chronic treatment with clenbuterol impairs Ca2+ homeostasis and this could contribute to the remodeling and functional impairment of fast-twitch skeletal muscle.


Editor: Laszlo Csernoch, University of Debrecen, Hungary

Received November 13, 2013; Accepted May 26, 2014; Published June 27, 2014

Copyright: © 2014 Sirvent et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by World Anti Doping Agency (http://www.wada-ama.org/en/), French Ministry of youth and sports (http://www.sports.gouv.fr/), Fondation de Francais des Jeux (http://www.groupefdj.com/fr). Drs Olivier Galbes and A Douillard held a graduate fellowship from the Ministère de la Recherche et de la Technologie (http://www.enseignementsup-recherche.gouv.fr/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: Pascal.Sirvent@univ-bpclermont.fr

Introduction

Clenbuterol is a β2-selective adrenergic receptor agonist primarily used for treating asthma. Like other β-adrenoceptor agonists, clenbuterol can induce skeletal muscle hypertrophy, by stimulating protein synthesis and inhibiting proteolysis [1,2]. Therefore, many studies have focused on the potential use of clenbuterol and some other β-adrenoceptor agonists to counteract muscle wasting associated with many pathological conditions [3]. Although clenbuterol has positive effects on skeletal muscle mass, some studies also reported myotoxic effects on heart and skeletal muscles [4,5]. Moreover, it is well documented that administration of β-adrenoceptor agonists, such as clenbuterol, results in a dramatic shift from a slow-oxidative to fast-glycolytic muscle fiber type profile [6,7,8]. This change in muscle fiber composition increases muscle fatigue, as reported after chronic administration of β-adrenoceptor agonists [9].

Clenbuterol effects on skeletal muscle seem to be fiber-type specific. Indeed, clenbuterol treatment causes hypertrophy only of fast skeletal muscle fibers [10]. Conversely, its myotoxic effects selectively target slow fibers [4,5,11,12].

The cellular mechanisms explaining the effects of chronic β-adrenoceptor agonist administration on skeletal muscle are not completely understood. Regulation of intracellular Ca2+ concentration is implicated in many cellular processes, such as excitation-contraction coupling, cell survival, energetic metabolism and gene transcription signaling [13]. Following depolarization, the Ca2+ transient, which is mainly elicited by the Ca2+ release from Ryanodine receptors (RyR) and is strongly influenced by sarcoplasmic reticulum (SR) Ca2+ load, is a major determinant of skeletal muscle functional properties. Acute administration of clenbuterol on skinned skeletal muscle fibers has a direct effect on sarcoplasmic reticulum (SR) Ca2+ release [14,15]. In cardiac muscle, chronic administration of clenbuterol increases SR Ca2+ content and the Ca2+-transient amplitude [16]. However, detailed studies on the impact of chronic clenbuterol treatment on calcium (Ca2+) homeostasis in skeletal muscle are lacking. Therefore, in this study, we assessed the effect on muscle Ca2+ homeostasis of chronic treatment (21 days) with clenbuterol in male Wistar rats.
Real time laser scanning confocal microscopy was used to investigate Ca\(^{2+}\)-transient amplitude, Ca\(^{2+}\) spark spatio-temporal properties, which reflect RyR functional properties, and SR Ca\(^{2+}\) load in EDL muscles. In addition, we also evaluated the effects of clenbuterol treatment on Ca\(^{2+}\)-activated proteolysis because it could be altered by Ca\(^{2+}\) homeostasis disturbances. EDL muscles have a fast-glycolytic phenotype and were chosen because they are less affected by myonecrosis and they are more sensitive to clenbuterol-induced hypertrophy [4,10]. Moreover, while the acute inhibitory effects of clenbuterol on force and Ca\(^{2+}\) transients in rat slow-twitch soleus muscle have already been described [15], its effects on fast-twitch skeletal muscles are less known.

**Materials and Methods**

**Animals**

This study was approved by the Ethics Committee on Animal Experimentation of the Languedoc Roussillon Region, France, in accordance with the guidelines from the French National Research Council for the Care and Use of Laboratory Animals ( Permit Number: CEEA-LR-1069). Surgery was performed under sodium pentobarbital anesthesia and all efforts were made to minimize suffering. Twenty-two 6-weeks/old Wistar male rats (body mass: 236.3 ± 3.8 g) were randomly allocated to the control (CTR; n = 11 animals) or clenbuterol-treated (CBL; n = 11 group). They were housed in standard cages with a 12 h:12 h light-dark cycle and provided with food and water ad libitum. Every day at 9 am for 21 days, rats were weighed and received a subcutaneous injection of clenbuterol (4 mg.kg\(^{-1}\).day\(^{-1}\) diluted in saline solution) or of an identical volume of saline vehicle (CTR). Rats were sacrificed with a lethal dose of pentobarbital sodium 24 h after the last injection.

**Muscle preparation**

For muscle contraction studies and Ca\(^{2+}\)-signaling measurements, intact EDL muscles were surgically dissected and immediately placed in a custom-built Plexiglas chamber filled with Tyrode solution (121 mM NaCl, 5.0 mM KCl, 1.8 mM CaCl\(_2\), 0.5 mM MgCl\(_2\), 0.4 mM NaH\(_2\)PO\(_4\), 24 mM NaHCO\(_3\), 0.1 mM EDTA 0.1, 5.5 mM glucose) equilibrated with 95% O\(_2\)-5% CO\(_2\) gas and maintained at 25°C. The pH was set to 7.4. These conditions are optimal for maintaining muscle viability in vivo for the duration of the experimental protocol.

For calf activity measurements, EDL muscles were homogenized in ice-cold buffer (20 mM Tris-HCl, 1.5 mM EDTA, 5 mM EGTA, 1 mM DTT 1, 0.15 mM Pefabloc, 5.8 nM Pepstatin A) and then centrifuged (1000 g for 10 min, 4°C). Supernatants were stored at −80°C. The protein concentration of supernatants was determined using the bicinchoninic acid (BCA) protein assay (Pierce, Interchim, Montluc\(_{\text{o}}\)on, France).

For western blotting, muscles were homogenized in ice-cold lysis buffer (20 mM Tris, 100 mM NaCl, 1 mM EGTA, 20 mM NaF, 5% Triton X-100, 0.15 mM Pefabloc, 5.8 nM Pepstatin A) and then centrifuged (12 000g for 20 min, 4°C). Supernatants were stored at −80°C.

**Muscle phenotype and cross-sectional areas**

Muscle phenotype was determined on cryosections (6 μm) by myosin ATPase histochemical staining as previously described [11]. The muscle-fiber cross-sectional area (CSA) was determined using the ImageJ analysis software and is expressed in μm\(^2\).

**Muscle fiber contractile function**

EDL muscle fiber contractile properties were assessed in vitro according to the methods described in detail previously [7]. After 15-min equilibration in the bath, muscles were connected to a force transducer/length servomotor system (model 305B, Cambridge Instruments, Aurora Scientific Inc, Ontario, Canada) and were stimulated along their entire length with platinum wire electrodes. The optimum muscle length (L\(_{0}\)), i.e. the muscle length producing maximal twitch tension, was determined. All subsequent measurements were made at L\(_{0}\). The tension-frequency response was then determined (701B Stimulator, Aurora Scientific Inc, Ontario, Canada) using stimulation trains of 500-ms, with pulse duration of 0.5 ms at frequencies of 1–100 Hz. Stimulation trains were separated by one-min interval. The maximum isometric tetanic tension (P\(_{0}\)) was then determined. Three minutes after the tension-frequency determination, the resistance to fatigue was evaluated using a low-frequency fatigue protocol of 50-hz trains of 700 ms delivered every 2 s for 5 min [17]. The muscle fatigue index (T\(_{\text{fat}}\)) was defined as the time taken to produce a 50% reduction from the initial maximum power output. After all measurements, muscles were removed from the bath, trimmed of the connective tissue, blotted dry and weighed on an analytical scale. The specific force (S\(_{\text{P0}}\), expressed in N/cm\(^2\)) was calculated by dividing the tension (P\(_{0}\)) by the whole-muscle CSA. The whole-muscle CSA was determined by dividing the muscle volume (obtained by dividing the muscle mass by the muscle density, assumed to be 1.06 g/cm\(^3\)) by the average fiber length (L\(_{f}\)). The specific force was determined by multiplying L\(_{f}\) by 0.44, which is the previously determined fiber length to muscle length ratio for the EDL muscle [7].

**Ca\(^{2+}\)-transient measurements**

Intact EDL muscles were loaded with 50 μM Rhod-2 AM (Molecular Probes, Eugene, OR), a fluorescent probe for intracellular Ca\(^{2+}\), in Krebs-Ringer solution for 1 h. Muscles were then mounted under stretch (between 3.1 and 3.4 μm, approximately the sarcomere length) to suppress movement artifacts [19]. Action-potentials and their associated Ca\(^{2+}\) transients were triggered by field stimulation with a single 2 ms pulse just above the stimulation threshold for visible fiber contraction under a microscope. Fluorescence images were acquired in line-scan mode (spatial [x] vs. temporal [t], 1.5 ms/line) with a Zeiss (Le Pecq, France) LSM 510 NLO confocal system (25 μm oil immersion, NA = 0.8), as previously reported [19]. Multiphoton excitation was obtained by using a 5-W Chameleon pulsed Ti:sapphire laser (Coherent, Orsay, France) tuned at 835 nm. The emitted fluorescence was recorded at ~560 nm. Single-fiber Ca\(^{2+}\)-transients were identified on raw fluorescence microscopy images. Image strips of the manually identified area of a single fiber were extracted. After subtracting the photomultiplier tube (PMT) offset current, strip images were converted to ΔF/F, where F is the fiber mean resting fluorescence calculated from the image area preceding the action-potential stimulation and the subsequent Ca\(^{2+}\)-transient. The temporal fluorescence time courses of each fiber were generated by spatial averaging of the ΔF/F images, resulting in the mean spatial F value for each temporal coordinate.

**Ca\(^{2+}\)-spark measurements**

Local Ca\(^{2+}\)-release events (i.e., Ca\(^{2+}\)-sparks) were measured as previously reported [20]. Muscle samples were immediately placed in an intracellular-like buffer (140 mM K-glutamate, 10 mM HEPES, 20 mM phosphocreatine, 5 mM Na\(_{2}\)ATP, 4.53 mM MgCl\(_2\), 1 mM EGTA, 0.29 mM CaCl\(_2\), and 2 mM malate, pH 7.0). Single fibers were manually dissected under a dissecting
microscope (Stemi 200; Zeiss, Le Peck, France), mounted in an experimental chamber containing the internal-like buffer, and permeabilized by adding 0.01% saponin at room temperature for 30 s. Fibers were slightly stretched to the sarcomere length (approximately 2.9–3.2 μm) to reduce movement artifacts. Fibers were bathed in internal-like buffer containing 50 μM of Fluo-3 (pentapotassium salt; Teflabs, Austin, TX), a fluorescent Ca²⁺ indicator. Fluorescence images were acquired with the confocal system operated in line-scan mode (x vs. t, 1.5 ms/line). Fluo-3 was excited with an argon/krypton laser at 488 nm and fluorescence was recorded at 525 nm. Image acquisition was performed along the fiber longitudinal axis. Potential spark areas were empirically identified using an auto-detection algorithm [21]. The mean F value of the image was calculated by summing and averaging the temporal F at each spatial location, while ignoring potential spark areas. This F value was then used to create a ΔF/F image pixel by pixel. Following a three-point smoothing routine, potential spark locations were visualized manually and their spatio-temporal properties analyzed as described previously [19,22]. We limited our analysis to Ca²⁺-spatio-temporal properties analyzed as described previously [23]. We thus investigated whether the EDL muscle hypertrophy and shift to a fast-glycolytic muscle fiber type profile induced by CBL treatment led to a significant increase in muscle mass compared to controls (+22%; 220.9±5.4 mg CBL vs 176.3±8.3 CTL group; p<0.001; n = 11 rats/group). Muscle fiber types were identified based on the extent of myosin ATPase staining (Fig. 1A). As seen in Fig. 1B, CBL treatment led to an increase in the CSA of type I (+20%), type IIa (+17%) and type IIb (+72%) fibers. Fig. 1C shows that CBL treatment led to a shift from a slow-oxidative to a fast-glycolylytic fiber type profile. While the percentage of type I fibers did not change significantly, a 17% decrease in type IIa fibers and a 15% increase in type IIb fibers were observed (p<0.05).

Muscle functional features
Skeletal muscle mass is a key determinant of the force output. We thus investigated whether the EDL muscle hypertrophy and the shift to a fast-glycolytic muscle fiber type profile induced by CBL chronic treatment affected the force output. As expected, Po was markedly increased after 21 days of CBL treatment (+87.5±2.3%) compared to CTL, whereas the sPo values (i.e., normalization of the Po values to the whole-muscle CSA), were not different between groups (Fig. 2A). Recording of the decline in tension in CTL and CBL-treated EDL muscles during the 3-min fatigue protocol (Fig. 2B) showed that the initial tension was higher than.
Ca\textsuperscript{2+}-signaling is impaired by chronic treatment with clenbuterol

As Ca\textsuperscript{2+} signaling is a major regulator of skeletal muscle plasticity and functional properties, we evaluated whether CBL treatment could impair Ca\textsuperscript{2+} signaling and, more specifically, the frequency and spatio-temporal properties of spontaneous Ca\textsuperscript{2+} sparks, which reflect RyR gating properties. Spontaneous Ca\textsuperscript{2+} spark were monitored using a confocal system operated in line-scan mode (Fig. 3A). Analysis of their spatio-temporal properties indicated that the Ca\textsuperscript{2+} spark amplitude (Fig. 3B) and frequency (Fig. 3C) were drastically reduced in EDL muscles of rats treated with CBL (~30% and ~59%, respectively, p<0.01 compared to controls), but their temporal properties were not significantly altered (rise time: 5.79±0.42 CBL vs 6.17±0.24 CTL; decay: 9.66±0.61 CBL vs 10.18±0.52 CTL). Assessment of SR Ca\textsuperscript{2+} load (peak of the signal, [23,24]) using 4-CmC showed a 43% decrease (p<0.01) in 4-CmC-induced Ca\textsuperscript{2+} release in CBL-treated compared to CTL EDL muscles (peak of the signal, Fig. 4A), indicating that the SR Ca\textsuperscript{2+} content is reduced following chronic CBL treatment. In accordance with these results, the global Ca\textsuperscript{2+}-transient amplitude was also reduced by 25% (p<0.01) after chronic CBL treatment compared to CTL (Fig. 4B).

Calpain activity

Calpains could be involved in skeletal muscle remodeling induced by CBL and their activity is influenced by Ca\textsuperscript{2+} signaling (calpain 1 and 2 are also called \(\mu\)- and m-calpain respectively, based on the \(\mu\)M or mM Ca\textsuperscript{2+} concentration needed for their activation). Global calpain activity, assessed by using spectrofluorimetric techniques, was drastically increased by 115% following CBL treatment (Fig. 5A, p<0.01 compared to CTL). This result was confirmed by immunoblotting experiments showing that autolysis of calpain 1 and calpain 2 was significantly increased in CBL-treated EDL muscle homogenates compared to CTL (from 8.14±3 to 18.73±5.94, p<0.01 for calpain 1; and from 19.74±3.41 to 60.34±6.64, p<0.01 for calpain 2) (Fig. 5B and C).

Discussion

Clenbuterol induces muscle hypertrophy and a phenotypic shift to a faster contractile profile. These properties have made clenbuterol a promising candidate for the treatment of various myopathies. However, several side effects have been reported following chronic treatment with clenbuterol and their mechanisms have not been clearly elucidated yet. In this study, we demonstrate that a 21-day treatment with clenbuterol is associated with substantial impairment of Ca\textsuperscript{2+} signaling. In particular, we found that chronic clenbuterol treatment decreases SR Ca\textsuperscript{2+} load (Fig. 4A) and this could explain the altered SR Ca\textsuperscript{2+} release properties. In particular, we found that the amplitude and frequency of elementary Ca\textsuperscript{2+}-release events (Ca\textsuperscript{2+}-sparks; Fig. 3) and global electrically-evoked Ca\textsuperscript{2+}-transients were reduced (Fig. 4B). We hypothesize that the decreased SR Ca\textsuperscript{2+} load after clenbuterol treatment may be due to a Ca\textsuperscript{2+} leak from RyR that could stimulate calpain activation and activity. Taken together, these alterations may contribute to the deleterious effects on muscle functionality reported following chronic treatment with clenbuterol.

Effects of clenbuterol treatment on skeletal muscle mass and fiber-type profile

Because of its positive effect on muscle mass, clenbuterol therapeutic potential in various pathological conditions affecting

Figure 1. Effects of chronic clenbuterol treatment on EDL fiber-type profile and muscle-fiber cross-sectional area. A, Histochemical staining for Myosin ATPase in 6 \(\mu\)m EDL cryosections from control (CTR; untreated group) and clenbuterol-treated (CLB) animals. The images correspond to staining for ATPase activity. The dark stain highlights fibers that mainly express Myosin Heavy Chain-I (MyHC-I); the light stain indicates fibers that mainly express MyHC-IIa; and the intermediate color corresponds to fibers that mainly express MyHC-IIx-IIb. B, Quantification of Myosin ATPase staining revealed an increased cross-sectional area for all fiber types following clenbuterol treatment (In \(\mu\)m\(^2\), type I from 689.52±29.56 to 828.53±35.96, type IIa from 860.84±40.37 to 1009.43±54.18, type IIx-b from 1968.74±173.64 to 3390.55±123.64). * p<0.05 compared to CTR. C, Treatment with clenbuterol induced a phenotypic shift from slow-oxidative to fast-glycolytic profile (type I from xxx ± xx to xxx ± xx, type IIa from xxx ± xx to xxx ± xx, type IIx-IIb from xx ± xx to xxx ± xx). Values are expressed as the mean ± SEM (7 animals in each group). * p<0.05 compared to CTR.

doi:10.1371/journal.pone.0100281.g001

and occurred earlier in CBL-treated EDL than in CTL muscles, in accordance with the increase in muscle mass and the phenotypic shift to a faster contractile profile observed in CBL-treated muscles. Conversely, the peak tetanic force decreased more quickly in CLB-treated muscles, and \(T_{\text{lim}}\) used as an index of resistance to fatigue, was significantly reduced compared to CTL. CBL treatment induced a mean 13±1% decrease in the \(T_{\text{lim}}\) (Fig. 2C; p<0.05), thus indicating that chronic treatment with CBL impairs muscle endurance.
Muscle tissue has been extensively evaluated. Studies in animal models have demonstrated beneficial effects of treatment with β2-agonists in conditions of muscular dystrophy, disuse, aging, denervation or amyotrophic lateral sclerosis [27,28,29,30,31,32].

Our 21-day treatment with clenbuterol led to marked EDL muscle hypertrophy (as indicated by muscle mass and muscle-fiber CSA measurements) and a phenotypic shift to a faster muscle profile. These effects are consistent with what is usually reported in the literature on fast skeletal muscle [3], thereby asserting the efficacy of our treatment.

Effects of clenbuterol treatment on skeletal muscle function

Surprisingly, while the effects of β2-agonists on skeletal muscle mass and phenotype have been extensively studied, few experiments have evaluated the impact of chronic treatment with clenbuterol on skeletal muscle function. In humans, 4-week clenbuterol treatment in orthopedic patients did not improve muscle absolute strength [33]. In rats, two studies have demonstrated negative effects of chronic clenbuterol treatment on exercise performance evaluated with the run-to-exhaustion treadmill [34], swimming or sprinting protocol tests [35]. Increased skeletal muscle fatigability was also reported following clenbuterol treatment in rat [7], an effect associated with reduced skeletal muscle oxidative capacity [36,37,38]. Moreover, muscle hypertrophy following chronic clenbuterol treatment increases the isometric force in fast-twitch skeletal muscle [7]. Our study confirms these previous results. The absolute force (P0) of EDL muscle was increased following clenbuterol treatment, while the specific force (sP0) was not different compared to controls, suggesting that the strength improvement was only due to the increased skeletal muscle mass. Analysis of representative recording of the decrease in EDL tension during the fatigue protocol.

Figure 2. Effects of chronic clenbuterol treatment on intact muscle contractile properties. A, Effects of clenbuterol (CLB) treatment for 21 days on EDL maximal isometric tension. Left graph, P0: maximal isometric tetanic tension, in mN; Right graph, sP0: specific maximal isometric tetanic tension, in N/cm². * p<0.05 compared to controls (CTR, untreated animals). B, Recordings show the decrease in tension resulting from the fatigue protocol in control EDL muscles (CTR) in which Tlim was almost 50 s and in clenbuterol treated EDL muscles (CLB) in which Tlim was about 34 s. Black dashed lines represent the maximal force and 50% of the initial force. The grey dashed line in the CLB panel represents 50% of the initial force of CTR for comparison. C, Mean ± SEM of the Tlim values/group (n = 15 for CTR; n = 22 for CLB). * p<0.05 compared to CTR. doi:10.1371/journal.pone.0100281.g002
highlighted that the initial tension was higher and appeared earlier in clenbuterol-treated EDL muscles than in untreated controls, in accordance with the increase in muscle mass and the phenotypic shift to a faster contractile profile. Fatigability of EDL muscles from clenbuterol-treated animals was nevertheless increased, as the peak tetanic force fell more quickly in clenbuterol-treated EDL muscles than in controls, and Tlim, used as an index of resistance to fatigue, was significantly reduced. This last result confirmed that

Figure 3. Effects of chronic clenbuterol treatment on Ca\textsuperscript{2+} spark amplitude and frequency. A, Representative line-scan ΔF/ΔF images of permeabilized skeletal muscle fibers from control (top) and clenbuterol-treated rats (bottom). B, Comparison of Ca\textsuperscript{2+}-spark amplitude in control (white bar graph) and clenbuterol-treated (black bar graph) animals. * p<0.05 compared to controls. C, Comparison of Ca\textsuperscript{2+}-spark frequency in control (white bar graph) and clenbuterol-treated (black bar graph) animals. Values are expressed as the mean ± SEM of 10 animals/group. * p<0.05 compared to controls.

doi:10.1371/journal.pone.0100281.g003

Figure 4. Effects of chronic clenbuterol treatment on SR Ca\textsuperscript{2+} load and Ca\textsuperscript{2+}-transient amplitude. A, Typical representation of calcium release elicited with 50 μM 4-chloro-m-cresol in control (CTR) and clenbuterol-treated (CLB) animals. Ca\textsuperscript{2+}-transient was imaged using fast time series of x-y confocal images. The amplitude (peak) of the signal was used as indicator of SR Ca\textsuperscript{2+} load. B, Typical representation of Ca\textsuperscript{2+}-transient triggered by field stimulation with a single 2 ms pulse in intact EDL muscles loaded with 50 μM Rhod-2 AM from control (CTR) and clenbuterol-treated (CLB) animals. C, Comparison of SR Ca\textsuperscript{2+}-load in control (CTR) and clenbuterol-treated (CLB) animals. Ca\textsuperscript{2+} release was elicited with 50 μM 4-chloro-m-cresol as shown in panel A. Values are expressed as the mean ± SEM of 10 animals in each group. * p<0.05 compared to controls. D, Quantification of Ca\textsuperscript{2+}-transient amplitude in control (CTR) and clenbuterol-treated (CLB) animals. Ca\textsuperscript{2+}-transients were triggered by field stimulation with a single 2 ms pulse as shown in panel B. Values are expressed as the mean ± SEM of 8 animals in each group. * p<0.05 compared to controls.

doi:10.1371/journal.pone.0100281.g004
Clenbuterol treatment negatively affects muscle endurance, in agreement with the phenotypic remodeling.

Ca²⁺ signaling impairment induced by clenbuterol treatment: a potential explanation for the impaired skeletal muscle function?

Ca²⁺ signaling plays a critical role in regulating skeletal muscle functional properties [13]. Different studies have demonstrated that acute application of clenbuterol on skeletal muscle fibers profoundly affects Ca²⁺ homeostasis, resulting in an increased Ca²⁺ leak from the SR. To date, no studies have evaluated the impact of chronic treatment with clenbuterol on skeletal muscle Ca²⁺ signaling. It is generally accepted that Ca²⁺ spark spatio-temporal properties and frequency reflect RyR1 function, as indicated by previous publications by our group. For instance, we previously used Ca²⁺ spark analysis to demonstrate the contribution of RyR in skeletal muscle pathophysiology [19,22]. Here, we found that the frequency and amplitude of spontaneous elementary SR Ca²⁺-release events (Ca²⁺-sparks) are reduced in EDL muscle fibers from clenbuterol-treated animals compared to control, suggesting changes in the SR Ca²⁺ release properties. The decreased amplitude of Ca²⁺ sparks could be explained by a decreased SR Ca²⁺ load as suggested by results in cardiac myocytes [39]. The presence of Ca²⁺ regulatory sites on the luminal side and on the myoplasmic side of the SR could explain how a reduction in SR Ca²⁺ content might affect Ca²⁺ release [40]. Indeed, it has been already shown that experimental decrease in SR Ca²⁺ load reduces Ca²⁺-spark frequency and amplitude in smooth muscle from rat [41]. In agreement with these results, we also found that in EDL muscles from clenbuterol-treated animals SR Ca²⁺ load was markedly reduced compared to untreated controls. The decrease in SR Ca²⁺ load could be a consequence of increased passive Ca²⁺ leak from the SR as already reported following acute clenbuterol treatment in mechanically skinned skeletal muscle fibers from rats [14]. We also observed a decrease in the amplitude of global Ca²⁺-transients in EDL muscles from clenbuterol-treated animals. This result is in accordance with the reduced amplitude of Ca²⁺ sparks and may also be a consequence of the reduced SR Ca²⁺ load. A reduction in Ca²⁺-transient amplitude could induce a decrease in the maximum capacity of force production by skeletal muscle, as already demonstrated following acute clenbuterol treatment [14]. However, we did not find any deterioration of the specific maximal isometric strength in EDL muscles following chronic treatment. An explanation of this apparent discrepancy could be a compensatory mechanism at the level of the myofilament Ca²⁺ sensitivity. Indeed, it has already been reported that chronic clenbuterol administration can improve Ca²⁺ sensitivity in rat slow-twitch skeletal muscle fibers [9].

Clenbuterol treatment increases calpain activities: a consequence of disturbed calcium homeostasis?

Ca²⁺ is a second messenger that regulates many signaling pathways. Therefore, Ca²⁺ homeostasis disturbances may also potentially disturb skeletal muscle metabolic and catabolic processes. For example, Ca²⁺ participates in the regulation of calpain activity. In particular, calpain 1 (μ-calpain) binds Ca²⁺ rapidly when the calcium concentration increases within a physiological range [42]. The role of calpain 2 (m-calpain) in the regulation of skeletal muscle function in vivo is more ambiguous, due to its apparent requirement of supraphysiological Ca²⁺ concentrations [43]. We hypothesized that a Ca²⁺ leak from the SR could mediate a decreased SR Ca²⁺ load and finally may reduce Ca²⁺-sparks and global Ca²⁺-transient amplitude. Another consequence of the increased Ca²⁺ leak from the SR could be the activation of calpains. Such association between SR Ca²⁺ release disturbances and calpain activation has already been reported in a mouse model of Duchenne muscular dystrophy (mdx mouse), a pathological condition that is associated with increased SR Ca²⁺ leak [46], reduced amplitude of Ca²⁺-transients [45] and increased calpains activity [44]. This example reinforces our hypothesis on a potential link between SR Ca²⁺ regulation disturbances and calpain activation. Recent studies have confirmed that chronic clenbuterol treatment in rats leads to increased calpain activities in fast-twitch skeletal muscles [11,47]. Previously, it has been reported that clenbuterol treatment could decrease calpain 1 activity and increase calpain 2 activity [47]. Here, we found that
chronic treatment with clenbuterol increases both calpain 1 and 2 activities in EDL muscles. While calpain activation seems to be necessary for clenbuterol-induced hypertrophy and the fiber profile shift [48], its activation might also cause deleterious effects on skeletal muscle, for example by promoting fiber necrosis, as already suggested [42]. Further studies are needed to elucidate more precisely the consequences of increased calpain activities and the link with disturbed Ca\textsuperscript{2+} homeostasis. In particular, it would be interesting to evaluate the potential role of calpain activation in SR Ca\textsuperscript{2+} disruption of E-C coupling and then SR Ca\textsuperscript{2+} release changes. Indeed, Ca\textsuperscript{2+}-activated proteases can induce proteolysis of SR Ca\textsuperscript{2+} release channels [49]. Moreover, in toad muscle fibers, Ca\textsuperscript{2+} exposure results in disruption of excitation-contraction coupling (E-C coupling) and titin, an effect possibly mediated, at least in part, by Ca\textsuperscript{2+}-activated proteases [50].

Similar results have been reported in mammalian skeletal muscle fibers in which calpain 1 was considered a good candidate to explain the Ca\textsuperscript{2+}-induced disruption of E-C coupling [51], potentially mediated by juncophilin proteolysis [52]. Based on these studies, we could hypothesize that increased calpain activity induced by clenbuterol treatment might contribute to the disruption of E-C coupling and then SR Ca\textsuperscript{2+}-release, leading to a functional impairment of skeletal muscle.

**Conclusion**

In this study we demonstrate that chronic clenbuterol treatment induces significant changes in various Ca\textsuperscript{2+} signals associated with excitation-contraction coupling in fast-twitch skeletal muscles. This effect occurs in association with increased calpain activities. Together, these alterations might contribute to the structural and functional adaptations of skeletal muscle to chronic clenbuterol treatment. As clenbuterol is considered a good candidate for the treatment of muscle disuse, our study underlines that more experiments are necessary to further elucidate the impact of chronic clenbuterol treatment on muscle metabolism and function.

**Acknowledgments**

This work was supported by the World Anti-Doping Agency, French Ministry of Youth and Sports, Fondation Francaise des Jeux, Olivier Galbes and A Douillard had a studentship from the Ministère de la Recherche et de la Technologie (MRT).

**Author Contributions**

Conceived and designed the experiments: PS GP RC AL. Performed the experiments: PS AD OG CR. Analyzed the data: PS AD OG CR AL. Contributed reagents/materials/analysis tools: RC AL. Wrote the paper: PS AD CR GP RC AL.

**References**


